A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Pirfenidone (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms EPOS
- 26 Aug 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.
- 26 Aug 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 26 Aug 2019 Status changed from recruiting to active, no longer recruiting.